NetworkNewsBreaks – Willow Biosciences Inc. (TSX

NetworkNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) to Receive Advisory Services, Funding for Rare Cannabinoid Development Platform

Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), today announced that its subsidiary, Willow Analytics Inc., will receive advisory services and conditional funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) supporting a research and development project to advance production of its varin cannabinoids using its proprietary biosynthetic platform. “We welcome the advice and funding from NRC IRAP to support our rare cannabinoid development platform,” said Dr. Mathias Schuetz, Willow’s vice president of Research and Development, in the news release. “This support is an important catalyst for us to advance our strain development capabilities and will enable us to progress from lab-scale work to pre-commercialization scale up.”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer